: The burden of increasing cancer incidence among the population, and, in particular, of prostate cancer in men living in highly developed countries, brings with it, on one hand, the need for new devices that allow a faster and earlier diagnosis, ideally in a non-invasive way and with low consumption of expensive reagents, and on the other the need for the assessment of new in vitro models that allow a more reliable assessment of cancer features, including its microenvironment and sensibility to different drugs. At the crossroads of these features, microfluidic devices are found. These, taking advantage of the chemical-physical properties of cells and human samples, have demonstrated great sensitivity and sensibility at an on-chip scale. Many fields of biomedical sciences have tried to exploit all their potentialities: from the detection of antigens in the early phases of the disease (when they are very low concentrated, but the treatment is more effective) to isolation and characterization of circulating tumor cells. However, the development of in vitro 3D models to better assess and comprehend the fundamental dynamics of tumor microenvironment and metastasis using 3D bioprinting techniques. The aim of the present review is to describe the potential of these two different cutting-edge technologies for the detection and treatment of prostate cancer, in the perspective of a possible future combination of them that allows scientists to fill the gaps present in the field to improve patient care and treatment.

中文翻译：

---

用于癌症检测和药物治疗的 3D 生物打印和微流体设备：聚焦前列腺癌

：人口中癌症发病率增加的负担，特别是生活在高度发达国家的男性前列腺癌的负担，一方面需要能够更快、更早诊断的新设备，最好是在另一方面，需要评估新的体外模型，以便更可靠地评估癌症特征，包括其微环境和对不同药物的敏感性。在这些特征的交叉点上，出现了微流体装置。这些利用细胞和人类样本的化学物理特性，在芯片规模上表现出了极高的灵敏度和敏感性。生物医学的许多领域都试图开发其所有潜力：从疾病早期阶段的抗原检测（此时抗原浓度非常低，但治疗更有效）到循环肿瘤细胞的分离和表征。然而，体外 3D 模型的开发可以利用 3D 生物打印技术更好地评估和理解肿瘤微环境和转移的基本动态。本综述的目的是描述这两种不同的尖端技术在检测和治疗前列腺癌方面的潜力，从未来可能将它们结合的角度来看，使科学家能够填补该领域存在的空白改善患者护理和治疗。